As of May 22
| +0.11 / +0.77%|
The 3 analysts offering 12-month price forecasts for Endocyte Inc have a median target of 18.00, with a high estimate of 20.00 and a low estimate of 15.00. The median estimate represents a +25.00% increase from the last price of 14.40.
The current consensus among 4 polled investment analysts is to Buy stock in Endocyte Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.